This study analyzed the SEER database and found that the pathological characteristics of previous breast cancer, HER2 expression status, hormone receptor status, and pathological grade did not significantly affect the mortality risk of patients with recurrent stage I NSCLC. This evidence concerns the gene ERBB2 and breast cancer.